- ... designed to test the hypothesis that NSAIDs, either selective (celecoxib) or nonselective (naproxen) cyclooxygenase-2 inhibitors, would work for the primary prevention of CATD. 255 – 258 The trial had three ...
- ... Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006 Apr;101(4):701– ...
- ... Thai. 2009] Gastrointestinal and cardiovascular risk of non-selective NSAIDs and ... for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic ...
- ... from the market after a long-term polyp prevention trial found an increased risk of myocardial infarction compared with placebo. 20 On December 9, 2004, the FDA issued a black-box warning for the selective COX-2 inhibitor valdecoxib for life-threatening skin reactions and increased ...
- ... thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. ... an international consensus statement. Lancet Oncol. 2009; 10 ( ...
- ... randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. ... inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal ...
- ... the overall pooled estimate for all COX-2 selective NSAIDs, and just met ... by specific COX-2 inhibitor, nor were estimates of CV risk with specific ...
- ... and inpatient hospitalizations), and comedication with nonopioid agents (selective ... NSAIDs: nonsteroidal antiinflammatory drugs; PTSD=post-traumatic stress ...
- ... G, et al.: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for ... J, et al.: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal ...
- ... explicitly referred to K.6. Non-specialist management – selective COX-2 inhibitors View in own window Reference Reason for exclusion ... 33-37 All participants had already tolerated a selective COX-2 inhibitor Di Leo E, Aloia AM, Nettis E, Cardinale ...
69 results